Herzuma-capecitabine/Cisplatin for Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Status
- COMPLETED
- Phase
- PHASE3
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
- Status
- TERMINATED
- Phase
- PHASE2
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Status
- COMPLETED
- Phase
- PHASE2
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
- Status
- UNKNOWN
- Phase
- PHASE2
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
- Status
- UNKNOWN
- Phase
- PHASE2
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- Status
- UNKNOWN
- Phase
- PHASE2
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1